会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 41. 发明公开
    • 흑마늘 추출물을 유효성분으로 포함하며 단백질 생산용 세포를 배양하는 배지에 첨가하기 위한, 배지 첨가용 조성물
    • 蛋白质生产细胞的培养基的添加组合物,其中含有作为活性成分的黑加拿大提取物
    • KR1020120135451A
    • 2012-12-14
    • KR1020110054202
    • 2011-06-03
    • (주)아이커스트
    • 양성범이용권최상곤이지영전복환정혜진
    • C12N5/02C12N5/12
    • PURPOSE: A medium additive composition containing black garlic extract is provided to enhance cell ability of producing proteins and to produce bio pharmaceutical products. CONSTITUTION: A medium additive composition for culturing protein producing cells contains black garlic extract as an active ingredient. The cells are hydridoma cells for producing proteins. The black garlic extract is prepared using water or low carbon number alcohol. The black garlic extract is a fraction which is prepared by extracting black garlic with ethanol and performing ultrafiltration. A cell culture method for enhancing protein production comprises a step of adding the composition to a medium for culturing the cells. [Reference numerals] (AA) Black garlic+solvent; (BB) Producing garlic concentrate liquid by mixing with mixer(20%, w/v); (CC) Centrifuging(3,000rpm, 30 minutes); (DD) Removing precipitate; (EE) Aseptic black garlic concentrate(BAG); (FF) Germ filtration; (GG) Ultrafiltration(10kDa); (HH,LL,QQ,RR) Freeze-drying; (II) Black garlic extract fraction liquid; (JJ) Filtered liquid(under 10kDa); (KK) Supernatant(10kDa or more); (MM) Nanofiltration(3kDa); (NN) Black garlic extract fraction liquid(>10kDa); (OO) Filtered liquid(under 30kDa); (PP) Supernatant(under 3kDa); (SS) Black garlic extract fraction liquid(3kDa); (TT) Black garlic extract fraction liquid(3-10kDa)
    • 目的:提供含有黑蒜提取物的中等添加剂组合物,以增强细胞生产蛋白质的能力和生产生物制药产品。 构成:培养蛋白质生成细胞的培养基添加剂组合物含有黑蒜提取物作为活性成分。 细胞是用于产生蛋白质的水母细胞。 黑蒜提取物是使用水或低碳酒精制备的。 黑蒜提取物是通过用乙醇提取黑蒜并进行超滤制备的一部分。 用于增强蛋白质产生的细胞培养方法包括将组合物添加到用于培养细胞的培养基中的步骤。 (AA)黑蒜+溶剂; (BB)通过与混合器(20%,w / v)混合生产大蒜浓缩液; (CC)离心(3,000rpm,30分钟); (DD)去除沉淀物; (EE)无菌黑蒜精(BAG); (FF)细菌过滤; (GG)超滤(10kDa); (HH,LL,QQ,RR)冷冻干燥; (二)黑蒜提取液; (JJ)过滤液(10kDa以下); (KK)上清液(10kDa以上); (MM)纳滤(3kDa); (NN)黑蒜提取物级分液体(> 10kDa); (OO)过滤液(30kDa以下); (PP)上清液(3kDa以下); (SS)黑蒜提取物级分液体(3kDa); (TT)黑蒜提取物级分液体(3-10kDa)
    • 47. 发明公开
    • 가용형 LOX―1에 대한 단일 클론 항체
    • 单克隆抗体可溶于LOX-1
    • KR1020090039802A
    • 2009-04-22
    • KR1020097003565
    • 2007-07-27
    • 시오노기세야쿠 가부시키가이샤
    • 고미나미고로나카무라마사히로구메노리아키오타히데키
    • C07K16/28C12N5/12C12P21/08
    • C07K16/28C07K2317/92
    • It is intended to provide a monoclonal antibody that specifically recognizes human soluble LOX-1, particularly a monoclonal antibody with a dissociation constant (Kd) for human soluble LOX-1 of 1 x 10-9 (M) or less. The antibody can be produced from a hybridoma prepared by a method including the following steps of: (1) immunizing a non-human animal with a prokaryotic cell-derived human LOX-1 extracellular domain; (2) collecting antibody-producing cells from the animal; (3) fusing the antibody-producing cells with myeloma cells; (4) selecting hybridomas that produce a monoclonal antibody reacting with the human LOX-1 extracellular domain from the fused cells obtained in the above step; and (5) selecting a hybridoma that produces a monoclonal antibody reacting with a eukaryotic cell-derived human LOX-1 extracellular domain from the selected hybridomas.
    • 旨在提供特异性识别人可溶性LOX-1的单克隆抗体,特别是具有1×10 -9(M)以下的人可溶性LOX-1的解离常数(Kd)的单克隆抗体。 抗体可以由通过包括以下步骤的方法制备的杂交瘤产生:(1)用原核细胞来源的人LOX-1细胞外结构域免疫非人动物; (2)从动物收集产生抗体的细胞; (3)将抗体产生细胞与骨髓瘤细胞融合; (4)从上述步骤获得的融合细胞中选择产生与人LOX-1细胞外结构域反应的单克隆抗体的杂交瘤; 和(5)选择产生与来自所选杂交瘤的真核细胞来源的人LOX-1细胞外结构域反应的单克隆抗体的杂交瘤。
    • 50. 发明公开
    • 인간 CTRP1을 특이적으로 인식하는 단일클론 항체 및이를 생산하는 하이브리도마 세포
    • 生产单克隆抗体对人类CTRP1和混合生产的单克隆抗体的杂交体
    • KR1020070109347A
    • 2007-11-15
    • KR1020060042197
    • 2006-05-11
    • 숙명여자대학교산학협력단
    • 양영김근영
    • C12N5/12C07K16/18
    • A hybridoma cell is provided to secret a monoclonal antibody capable of specifically recognizing human CTRP1(C1q-TNF related protein-1) and immunoprecipitating it. A monoclonal antibody is provided to detect the CTRP1 protein economically and conveniently and be widely used for diagnosing, preventing and treating obesity or diabetes. A hybridoma cell E21H7 produces mouse monoclonal antibodies binding to human CTRP1 and is deposited as a deposition no. KCTC 10944BP. A method for producing the hybridoma cell E21H7 comprises the steps of: (a) immunizing mouse using a fusion protein of human CTRP1; (b) fusing a spleen cell of the immunized mouse into myeloma cell and then culturing it; and (c) selecting hybridoma cells producing monoclonal antibodies specific to the human CTRP1 from the fused hybridoma cells. An IgG2a type monoclonal antibody specific to human CTRP1 is prepared by the hybridoma cell E21H7.
    • 提供了一种杂交瘤细胞来保护能够特异性识别人类CTRP1(C1q-TNF相关蛋白-1)并免疫沉淀的单克隆抗体。 提供单克隆抗体经济地和方便地检测CTRP1蛋白,被广泛用于诊断,预防和治疗肥胖或糖尿病。 杂交瘤细胞E21H7产生与人CTRP1结合的小鼠单克隆抗体,并作为沉积物沉积。 KCTC 10944BP。 制备杂交瘤细胞E21H7的方法包括以下步骤:(a)使用人CTRP1的融合蛋白免疫小鼠; (b)将免疫小鼠的脾细胞融合入骨髓瘤细胞,然后培养; 和(c)从融合的杂交瘤细胞中选择产生对人CTRP1特异性的单克隆抗体的杂交瘤细胞。 通过杂交瘤细胞E21H7制备对人CTRP1特异性的IgG2a型单克隆抗体。